Rigel Pharmaceuticals (FRA:RI2) Net Margin %: 14.71% (As of Mar. 2026)


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
78 GF Score
Price €29.47
GF Value €23.45
! 8 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Net Margin %?

Rigel Pharmaceuticals FRA:RI2 +4.43% 78 Net Margin % is 14.71% as of Mar. 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 78/100 and a GF Value™ of €23.45. The stock has 8 warning signs investors should review. Among 947 Biotechnology companies, Rigel Pharmaceuticals ranks better than 98.2% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Rigel Pharmaceuticals's Net Income for the three months ended in Mar. 2026 was €7.5 Mil. Rigel Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was €50.9 Mil. Therefore, Rigel Pharmaceuticals's net margin for the quarter that ended in Mar. 2026 was 14.71%.

The historical rank and industry rank for Rigel Pharmaceuticals's Net Margin % or its related term are showing as below:

FRA:RI2' s Net Margin % Range Over the Past 10 Years
Min: -1739.34   Med: -38.05   Max: 124.72
Current: 121.51

FRA:RI2's Net Margin % is ranked better than
98.2% of 947 companies
in the Biotechnology industry
Industry Median: -89.56 vs FRA:RI2: 121.51

Rigel Pharmaceuticals  (FRA:RI2) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Rigel Pharmaceuticals Net Margin % Related Terms

Rigel Pharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Net Margin % Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.00 -48.71 -21.47 9.75 124.72

Rigel Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.46 58.62 40.17 384.04 14.71

FRA:RI2 vs CBIO, TRAX, GYRE: Net Margin % Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rigel Pharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Net Margin % falls into.


FRA:RI2
78GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Rigel Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=313.438/251.317
=124.72 %

Rigel Pharmaceuticals's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=7.486/50.878
=14.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 14.71% mean?
Rigel Pharmaceuticals (FRA:RI2) has a Net Margin % of 14.71% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Rigel Pharmaceuticals and its competitors. According to the industry distribution chart, Rigel Pharmaceuticals ranks #17 out of 947 companies in the Biotechnology industry, placing it in the top 1.8%.
Is Rigel Pharmaceuticals' Net Margin % too high?
Rigel Pharmaceuticals' current Net Margin % is 14.71%. Based on the distribution chart, Rigel Pharmaceuticals ranks #17 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rigel Pharmaceuticals has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Net Margin % compare to CBIO and TRAX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #17 out of 947 companies for Net Margin %. This places Rigel Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current Net Margin % is 14.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Net Margin % of 14.71%. The stock's GF Value™ is €23.45, compared to a current price of €29.47 — trading 25.7% above its estimated fair value. The current Net Margin % is 14.71%. Rigel Pharmaceuticals' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Net Margin % is 14.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €29.47 is trading 25.7% above its estimated GF Value™ of €23.45.

Key valuation signals for FRA:RI2:

  • Net Margin %: 14.71%
  • GF Value™: €23.45 vs. price of €29.47 (25.7% above fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
78GF Score

Get the complete analysis for FRA:RI2

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.47
Price
€23.45
GF Value